Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Regrowth from massage, update and integration

      in Is this regrowth?  2 upvotes 10 months ago
      The conversation discusses using scalp massage, balms like Ethera and L'Occitane, and dietary changes such as rosemary tea and tofu to address hair loss. The user is also considering high-intensity interval training and slow breathing to improve hair regrowth.

      community Rosemary out here changing lives for the better

      in Treatment  90 upvotes 2 years ago
      Rosemary oil is being used as an addition to minoxidil and finasteride for hair health, with mixed opinions on its effectiveness. Some users report positive results, while others see no benefit or experience adverse effects.

      community Ru58841 20mg….making my own solution

      in Treatment  1 upvotes 1 year ago
      The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.

      community Optimal Pyrilutamide (KX-826) Mix and application

      in Research/Science  9 upvotes 3 years ago
      The conversation discusses how to mix pyrilutamide for hair loss treatment, suggesting a mixture of 500mg pyrilutamide with 70% ethanol and 30% propylene glycol, and a potential application dose of 1mL. The user has not personally used pyrilutamide but has researched its preparation and application based on others' experiences.

      community Since there is so much hype for cosmeRNA and HMI-115...

      in Chat  44 upvotes 3 years ago
      Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.